Ikena Oncology’s (IKNA) Neutral Rating Reiterated at Wedbush

Ikena Oncology (NASDAQ:IKNA)‘s stock had its “neutral” rating restated by equities researchers at Wedbush in a research report issued on Monday,RTT News reports. They presently have a $2.00 target price on the stock. Wedbush’s price target suggests a potential upside of 30.72% from the stock’s current price.

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Ikena Oncology in a report on Monday, November 11th.

Ikena Oncology Price Performance

Ikena Oncology stock opened at $1.53 on Monday. The business has a 50 day simple moving average of $1.69 and a 200 day simple moving average of $1.69. The company has a market capitalization of $73.83 million, a PE ratio of -1.24 and a beta of 0.49. Ikena Oncology has a one year low of $1.22 and a one year high of $2.29.

Ikena Oncology (NASDAQ:IKNA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. Equities analysts anticipate that Ikena Oncology will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Ikena Oncology

Several large investors have recently made changes to their positions in the business. Blue Owl Capital Holdings LP lifted its stake in shares of Ikena Oncology by 5.1% during the second quarter. Blue Owl Capital Holdings LP now owns 4,091,118 shares of the company’s stock valued at $6,750,000 after acquiring an additional 200,000 shares during the period. BML Capital Management LLC raised its holdings in Ikena Oncology by 23.6% during the 3rd quarter. BML Capital Management LLC now owns 723,288 shares of the company’s stock worth $1,251,000 after purchasing an additional 138,174 shares during the last quarter. NEA Management Company LLC lifted its position in Ikena Oncology by 5.3% during the 3rd quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock valued at $1,038,000 after purchasing an additional 30,013 shares during the period. Sofinnova Investments Inc. grew its position in shares of Ikena Oncology by 230.7% during the 2nd quarter. Sofinnova Investments Inc. now owns 382,616 shares of the company’s stock worth $631,000 after buying an additional 266,904 shares during the period. Finally, Acadian Asset Management LLC raised its stake in shares of Ikena Oncology by 15.2% during the second quarter. Acadian Asset Management LLC now owns 325,713 shares of the company’s stock worth $536,000 after buying an additional 42,931 shares during the last quarter. Institutional investors own 75.00% of the company’s stock.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.